These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

577 related items for PubMed ID: 15389727

  • 1. QT prolongation through hERG K(+) channel blockade: current knowledge and strategies for the early prediction during drug development.
    Recanatini M, Poluzzi E, Masetti M, Cavalli A, De Ponti F.
    Med Res Rev; 2005 Mar; 25(2):133-66. PubMed ID: 15389727
    [Abstract] [Full Text] [Related]

  • 2. Molecular determinants of high-affinity drug binding to HERG channels.
    Mitcheson JS, Perry MD.
    Curr Opin Drug Discov Devel; 2003 Sep; 6(5):667-74. PubMed ID: 14579516
    [Abstract] [Full Text] [Related]

  • 3. Drug-induced QT interval prolongation--regulatory guidance and perspectives on hERG channel studies.
    Shah RR.
    Novartis Found Symp; 2005 Sep; 266():251-80; discussion 280-5. PubMed ID: 16050273
    [Abstract] [Full Text] [Related]

  • 4. [HERG K+ channel, the target of anti-arrhythmias drugs].
    Guan FY, Yang SJ.
    Yao Xue Xue Bao; 2007 Jul; 42(7):687-91. PubMed ID: 17882949
    [Abstract] [Full Text] [Related]

  • 5. Long QT syndrome in neonates: conduction disorders associated with HERG mutations and sinus bradycardia with KCNQ1 mutations.
    Lupoglazoff JM, Denjoy I, Villain E, Fressart V, Simon F, Bozio A, Berthet M, Benammar N, Hainque B, Guicheney P.
    J Am Coll Cardiol; 2004 Mar 03; 43(5):826-30. PubMed ID: 14998624
    [Abstract] [Full Text] [Related]

  • 6. Pentamidine-induced long QT syndrome and block of hERG trafficking.
    Kuryshev YA, Ficker E, Wang L, Hawryluk P, Dennis AT, Wible BA, Brown AM, Kang J, Chen XL, Sawamura K, Reynolds W, Rampe D.
    J Pharmacol Exp Ther; 2005 Jan 03; 312(1):316-23. PubMed ID: 15340016
    [Abstract] [Full Text] [Related]

  • 7. Predicting drug-hERG channel interactions that cause acquired long QT syndrome.
    Sanguinetti MC, Mitcheson JS.
    Trends Pharmacol Sci; 2005 Mar 03; 26(3):119-24. PubMed ID: 15749156
    [Abstract] [Full Text] [Related]

  • 8. A pharmacokinetic-pharmacodynamic model for the quantitative prediction of dofetilide clinical QT prolongation from human ether-a-go-go-related gene current inhibition data.
    Jonker DM, Kenna LA, Leishman D, Wallis R, Milligan PA, Jonsson EN.
    Clin Pharmacol Ther; 2005 Jun 03; 77(6):572-82. PubMed ID: 15961988
    [Abstract] [Full Text] [Related]

  • 9. The hERG potassium channel and hERG screening for drug-induced torsades de pointes.
    Hancox JC, McPate MJ, El Harchi A, Zhang YH.
    Pharmacol Ther; 2008 Aug 03; 119(2):118-32. PubMed ID: 18616963
    [Abstract] [Full Text] [Related]

  • 10. Inhibition of human ether-a-go-go-related gene K+ channel and IKr of guinea pig cardiomyocytes by antipsychotic drug trifluoperazine.
    Choi SY, Koh YS, Jo SH.
    J Pharmacol Exp Ther; 2005 May 03; 313(2):888-95. PubMed ID: 15722405
    [Abstract] [Full Text] [Related]

  • 11. Acquired QT interval prolongation and HERG: implications for drug discovery and development.
    Finlayson K, Witchel HJ, McCulloch J, Sharkey J.
    Eur J Pharmacol; 2004 Oct 01; 500(1-3):129-42. PubMed ID: 15464027
    [Abstract] [Full Text] [Related]

  • 12. Utility of hERG assays as surrogate markers of delayed cardiac repolarization and QT safety.
    Gintant GA, Su Z, Martin RL, Cox BF.
    Toxicol Pathol; 2006 Oct 01; 34(1):81-90. PubMed ID: 16507548
    [Abstract] [Full Text] [Related]

  • 13. Cardiac glycosides as novel inhibitors of human ether-a-go-go-related gene channel trafficking.
    Wang L, Wible BA, Wan X, Ficker E.
    J Pharmacol Exp Ther; 2007 Feb 01; 320(2):525-34. PubMed ID: 17095614
    [Abstract] [Full Text] [Related]

  • 14. HERG mutation predicts short QT based on channel kinetics but causes long QT by heterotetrameric trafficking deficiency.
    Paulussen AD, Raes A, Jongbloed RJ, Gilissen RA, Wilde AA, Snyders DJ, Smeets HJ, Aerssens J.
    Cardiovasc Res; 2005 Aug 15; 67(3):467-75. PubMed ID: 15958262
    [Abstract] [Full Text] [Related]

  • 15. A common antitussive drug, clobutinol, precipitates the long QT syndrome 2.
    Bellocq C, Wilders R, Schott JJ, Louérat-Oriou B, Boisseau P, Le Marec H, Escande D, Baró I.
    Mol Pharmacol; 2004 Nov 15; 66(5):1093-102. PubMed ID: 15280442
    [Abstract] [Full Text] [Related]

  • 16. Drug-induced block of cardiac HERG potassium channels and development of torsade de pointes arrhythmias: the case of antipsychotics.
    Calderone V, Testai L, Martinotti E, Del Tacca M, Breschi MC.
    J Pharm Pharmacol; 2005 Feb 15; 57(2):151-61. PubMed ID: 15720777
    [Abstract] [Full Text] [Related]

  • 17. Computer-aided prediction of QT-prolongation.
    Filz O, Lagunin A, Filimonov D, Poroikov V.
    SAR QSAR Environ Res; 2008 Feb 15; 19(1-2):81-90. PubMed ID: 18311636
    [Abstract] [Full Text] [Related]

  • 18. Prolong QT interval and "torsades de pointes" associated with different group of drugs.
    Gongadze N, Kezeli T, Antelava N.
    Georgian Med News; 2007 Dec 15; (153):45-9. PubMed ID: 18250496
    [Abstract] [Full Text] [Related]

  • 19. QT prolongation and torsade de pointes induced by fluoroquinolones: infrequent side effects from commonly used medications.
    Briasoulis A, Agarwal V, Pierce WJ.
    Cardiology; 2011 Dec 15; 120(2):103-10. PubMed ID: 22156660
    [Abstract] [Full Text] [Related]

  • 20. Probucol aggravates long QT syndrome associated with a novel missense mutation M124T in the N-terminus of HERG.
    Hayashi K, Shimizu M, Ino H, Yamaguchi M, Terai H, Hoshi N, Higashida H, Terashima N, Uno Y, Kanaya H, Mabuchi H.
    Clin Sci (Lond); 2004 Aug 15; 107(2):175-82. PubMed ID: 15043509
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.